Unlike traditional medications, RNA drugs encounter numerous barriers from the moment they enter the body until they reach their target cells. Unprotected RNA is inherently unstable under physiological conditions and is susceptible to enzymatic degradation by endogenous nucleases, often leading to its breakdown before reaching the target cells, significantly compromising therapeutic efficacy.
The LNP is a complex nanostructured entity that serves to protect the delicate RNA molecule from the harshly degrading nuclease environment in vivo while facilitating intracellular delivery. It comprises several lipid components, including an ionizable lipid that plays a central role in delivery efficacy. Intelligene is diligently refining the formulation of our RNAi drugs to optimize their delivery to target tissues and enhance efficacy.
Exosomes are small (~40-150 nm) extracellular vesicles (EVs) released from all cell types and found in body fluids and cell culture supernatants. They are generated by fusion of a specialized endosome, the multivesicular body (MVB), with the plasma membrane. Exosome has been identified as a perfect therapeutic agent due to their size, ease of crossing cell membranes and ability to communicate in native cellular language.
Engineered exosomes can deliver drugs without eliciting an immune response.
It's highly biocompatible and also biodegradable inside the body,
therefore making it without any potential toxicity issue and become an ideal drug deliver vehicle.
-
Biocompatibility
-
Biodegradability
-
High Penetration
-
Non-immunogenic
